Invion Limited (IVX) Fair Value & Analysis
Healthcare · AU · Market cap A$3.8M
Fair value as of: Jul 17, 2026
From 3 valuation models · updated today
Share price −14.6% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0320 – A$0.1450 · fair‑value band A$0.0461 – A$0.1205 · the A$0.0350 price screens below the A$0.0788 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Invion Limited (IVX) currently trades at A$0.0350, while our model-based Fair Value estimate is A$0.0788, implying the stock looks roughly 125.3% undervalued today. We read business quality at 23/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at A$3.0K. Fundamentals as of Jul 17, 2026
Our scenario range runs from A$0.0461 (bear case) to A$0.1205 (bull case); at A$0.0350, the current price sits below that range. The share trades about 76% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 125%, IVX screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Invion Limited reported revenue of A$0 in FY2025 versus A$2.3M in FY2021. Reported net income was −A$8.8M in FY2025.
Is IVX fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Invion Limited (IVX) undervalued?
What is the fair value of IVX?
What is the quality score of IVX?
What is the revenue of Invion Limited (IVX)?
What is the net profit margin of IVX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Invion Limited reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Invion Limited materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.